Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice

Transcription

1 Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and Women's Hospital Professor of Medicine and the Michael and Lee Bell Professor of Women's Health Harvard Medical School MMS Women s Health Forum Waltham, Massachusetts April 21, 2017 Faculty/Presenter Disclosure I have no financial conflicts of interest related to this presentation. 1

2 Hormone Therapy and Health Outcomes (One Size Does Not Fit All) things should be as simple as possible, but not any simpler. A. Einstein Objectives Review recent findings from the intervention and poststopping phases of the WHI. Describe patient characteristics, including age, time since menopause, underlying CVD risk factor status, and biomarker levels, that modify health outcomes on hormone therapy. Address the role of recent results from WHI and other studies in improving clinical decision making for hormonal vs non-hormonal therapy. 2

3 Number of Hot Flushes with Estrogen/Progestin (CEE+MPA of different doses) vs. Placebo Mean Adjusted Number* Placebo 0.625/ / / / Cycle Number of Hot Flushes Over 13 Cycles Source: Utian W, et al. Fertil Steril 2001; 75:

4 Non-Hormonal Medications: Efficacy for Hot Flashes Reduction Medication Dose in Frequency Paroxetine* mg 40 50% Venlafaxine mg 40% Escitalopram mg 30 40% Gabapentin mg 40 50% *Only FDA-approved nonhormonal prescription medication for treatment of hot flashes. Similar results for Pregabalin. Source: Stuenkel CA, et al. JCEM 2015; 100: Differential Effects of Estrogen on Early and Later Stages of Atherosclerotic Disease Source: Mendelsohn ME and Karas RH. Science 2005; 308:

5 HT and CHD: Meta-Analysis of Observational Studies Based on more than 40 observational studies of HT and CHD, the summary relative risks for CHD were 40-50% lower among current users of HT compared to never users (p<0.001). From: Grodstein F, Stampfer MJ. Prog Cardiovasc Dis 1995; 38:199. Key Differences Between the WHI and Observational Studies of Hormone Therapy (HT) WHI Observational Studies Age at HT initiation (mean) 63 yrs 52 yrs Time since menopause (mean) >12 yrs 1-3 yrs 5

6 Randomized Trials of HT and CVD Secondary Prevention: Heart and Estrogen/Progestin Replacement Study (HERS) Estrogen Replacement and Atherosclerosis Trial (ERA) Papworth HRT Atherosclerosis Study* Women s Estrogen for Stroke Trial (WEST) Estrogen in the Prevention of ReInfarction Trial (ESPRIT) Women s Angiographic Vitamin and Estrogen (WAVE) Trial Primary Prevention: Women's Health Initiative (WHI) Estrogen+Progestin Trial Estrogen-Alone Trial CEE±MPA except: *transdermal estradiol±neta, oral estradiol Women s Health Initiative (WHI), Ages Hormone Program Design Women who had no uterus at start of study Hysterectomy Women who had a uterus at start of study YES N= 10,739 NO N= 16,608 Conjugated equine estrogen (CEE) mg/d Placebo CEE mg/d + medroxyprogesterone acetate (MPA) 2.5 mg/d Placebo 6

7 WHI Estrogen+Progestin Trial Findings, July 2002 ( N=16,608; mean age 63 yrs; mean follow-up 5.2 yrs) Risks Benefits Coronary Heart Disease 29% Stroke 41% Pulmonary Embolism 113% Breast Cancer 26% Hip Fracture 34% Colorectal Cancer 34% Threshold Level STOPPED Early, Clear Harm Stopped 3.3 years early Adapted from: Writing Group for the Women s Health Initiative. JAMA 2002;288:321. WHI Estrogen-Alone and Health Outcomes (N=10,739; mean age 63.6 yrs; mean follow-up 6.8 yrs) Risks Stroke 39% Null CHD (0.91) Pulm Emb (1.34) Breast Cancer (0.77) Colorectal Cancer (1.08) Total Mortality (1.04) Global Index (1.01) Benefits Hip Fracture 39% STOPPED Early Threshold Level Stopped 1 year early Source: JAMA 2004; 291:

8 WHI Hormone Therapy Trials: Absolute Risks (cases per 10,000 person-years) for Outcomes in the Estrogen-Progestin and Estrogen-Alone Trials, by Age Group Age Age Age CEE+MPA Trial CHD Breast Cancer Stroke PE Colorectal Cancer Hip Fracture All-Cause Mortality Active Placebo CEE Alone Trial CHD Breast Cancer Stroke PE Colorectal Cancer Hip Fracture All-Cause Mortality Source: Manson JE, Chlebowski RT, Stefanick ML, et al. JAMA

9 WHI Estrogen-Alone Trial: Myocardial Infarction Results According to Age at Randomization Total MI Age Group HR (95% CI) ( ) ( ) ( ) *Similar results for CABG/PCI* P, trend by age = 0.02 MI = myocardial infarction p, trend by age group Source: Manson JE, Chlebowski RT, Stefanick ML, et al. JAMA Estrogen+Progestin Therapy and Risk of MI in WHI: Results According to Age and Time Since Menopause Time since Age HR Menopause Onset HR <10 yrs yrs * >20 yrs 1.99* P, trend 0.55 P, trend 0.01 * P-value <0.05 P for trend by age group Source: Manson JE, Chlebowski RT, Stefanick ML, et al. JAMA

10 Early vs. Late Intervention Trial with Estradiol (ELITE) Design Participants: 643 healthy recently postmenopausal women without preexisting CVD or diabetes. Study design: Randomized treatment (estradiol, placebo) x time since menopause (<6 years, >10 years). Intervention: Oral micronized 17β-estradiol 1 mg/d (+ vaginal micronized progesterone gel x 12 days/mo in women with a uterus). Placebos Outcomes: Primary: rate of change in Carotid IMT, up to 6 yrs. Other: CAC, contrast CT angiography (low power and not reported in detail). Source: Hodis H, et al. N Engl J Med ELITE: Carotid IMT by Treatment and Time Since Menopause Placebo >10 yrs P=0.29 Estradiol >10 yrs Placebo <6 yrs P=0.008 Estradiol <6 yrs P-value for interaction =0.007 Source: Hodis H, et al. N Engl J Med

11 Estrogen, Insulin Action, and Diabetes: Is Timing Everything? RCT of 46 women ( 6 vs 10 yrs since menopause). Treated with high-dose transdermal estradiol: 150 µg/day for a week. Test: insulin-mediated glucose disposal rate (GDR) via clamp studies pre- and post-tx. Results: Younger women: GDR and insulin sensitivity. Older women: GDR and insulin sensitivity. (Significant interaction by time since menopause) These findings suggest that estrogen s effects on insulin action differ by time since menopause. Source: Pereira RI, et al. J Clin Endocrinol Metab 2015; 100: WHI: Other Health Outcomes HRs similar by age for stroke, venous thrombosis/pulmonary embolism, breast cancer, and most other outcomes. *BUT* Much lower absolute risks in younger, compared to older, women. 11

12 Benefits and Risks of HT in Women Aged in the WHI HT Trials (per 1000 women over 5 years) CEE+MPA Trial Risks Benefits CHD Stroke DVT Breast Colorectal All All All-Cause Diabetes CA CA Cancers Fractures Mortality Risks CEE-Alone Trial 2.5 Benefits Sources: Data from Manson JE, et al. JAMA 2013, and Santen R, et al. J Wom Hlth Absolute Risks (Cases per 1000 Women Over 5 Years) by Age in the WHI HT Trials E+P Trial E-Alone Trial Total mortality Global Index Global index is a composite outcome of CHD, stroke, pulm embolism, breast cancer, colorectal cancer, endometrial cancer, hip fracture, and mortality. Source: Manson, Chlebowski, Stefanick, et al. JAMA 2013;310:

13 CHD Risk Associated with E+P or E-Alone (pooled) According to Baseline Biomarker Status in the WHI OR (95% CI) for P value HT Treatment Effect for Interaction LDL chol (mg/dl) < ( ) ( ) LDL/HDL Ratio* < ( ) ( ) Metabolic Syndrome No 0.97 ( ) Yes 2.26 ( ) Sources: Bray PF, et al. Am J Cardiol 2008; Wild RA, et al. Menopause WHI HT Trials: Summary of Results for Primary and Other Major Endpoints by Study Phase Major Endpoints Intervention Post Intervention CEE+MPA CEE CEE+MPA CEE CHD Breast cancer Stroke 0 0 PE Colorectal cancer Endometrial cancer 0 NA NA Hip fracture 0 0 All cause mortality Global index Source: Manson, Chlebowski, Stefanick, et al. JAMA 2013;310:

14 Transdermal Therapy and Low-Dose Regimens: Advantages over Oral/Conventional? Less effect on: Clotting factors Triglycerides C-reactive protein Blood pressure * But no large-scale randomized trials assessing relative safety (predominately observational data)* Are Lower Doses Safer? Blood Pressure: No effect on BP with low-dose o-cee or t-e2 in KEEPS, compared to SBP with mg o-cee or E+P in WHI. Stroke: In the Nurses Health Study, the risk of stroke was not increased for women taking 0.3 mg CE (RR 0.93); the mg dose was associated with risks similar to WHI. 1 MI: In a Danish National Registry, no associations were found with estrogen dose Grodstein F. Arch Intern Med 2008;168: Lokkegaard E. Eur Heart J 2008;29:

15 Bioidentical Market Explodes Prescriptions for compounded bioidentical hormones have skyrocketed. Developed into a billion dollar industry of products neither tested nor FDA regulated. Believed by millions of women to be safer and more effective. A free mobile app for menopause symptom management from The North American Menopause Society Clinical decision-support tool Available for iphones, ipads, and Android devices Dual mode for Clinicians and Women/Patients Learn more at: Menopause 2015; 22(3):[e-pub 10/13/14] or at 15

16 MenoPro/NAMS Algorithm and Free Mobile App Moderate-to-severe hot flashes and/or night sweats? (and inadequate response to behavioral/lifestyle modifications) No Yes See VVA algorithm Yes Assess CVD risk and time since menopause onset CVD Risk Over 10 Years (ACC/AHA Risk prediction score) Years Since Menopause Onset <5 6 to 10 >10 Low (<5%) HT OK HT OK Avoid HT Moderate (5% to 10%) High (>10%) Interested in HT and free of breast cancer, endometrial cancer, DVT/PE, CHD, stroke/tia, and other contraindications to HT? HT OK (consider transdermal) HT OK (consider transdermal) Avoid HT Avoid HT Avoid HT Avoid HT No Consider non-hormonal therapy: paroxetine mesylate, other SSRI/SNRIs, gabapentin, pregabalin, clonidine (CE/bazedoxifene also may be an option for women with an intact uterus) DECISION ABOUT DURATION OF USE: continued moderate-to-severe symptoms; patient preference; weigh baseline risks of breast cancer, CVD, and osteoporosis. Sources: Manson JE, et al. Menopause 2014 and Manson JE, Bassuk SS, Harrison s Conclusions Hormone therapy continues to have an important clinical role in the management of menopausal symptoms. Current evidence does not support the use of HT for the prevention of CVD or other chronic diseases (due to increased risk of VTE and stroke/breast CA [E+P] in all age groups). The best candidates for systemic HT are recently menopausal and symptomatic women in generally good health (low absolute risks and greater QOL benefits). Risk stratification and a personalized approach to decision making is recommended Additional studies of different HT formulations, doses, routes of delivery, and of non-hormonal options are needed. 16

17 Thanks to the Participants, Investigators, and Staff of WHI and other Research Studies Thank you! 17